Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012

High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856

MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins

Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652

Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease

Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431

Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state

Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359

Localized Surface Plasmon Resonance Spectroscopy and Sensing

Willets, K. A., & Duyne, R. P. V. (2006) · Annual Review of Physical Chemistry · doi:10.1146/annurev.physchem.58.032806.104607 · Cited by 6,162

Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade

Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962

Aβ Oligomers – a decade of discovery

Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938

P ROTOFIBRILS , P ORES , F IBRILS, AND N EURODEGENERATION : Separating the Responsible Protein Aggregates from The Innocent Bystanders

Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650

Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability

Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061

Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers

Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954

The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization

Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 892

Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine

De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882

Detection of a Biomarker for Alzheimer's Disease from Synthetic and Clinical Samples Using a Nanoscale Optical Biosensor

Haes, A. J., Chang, L., Klein, W. L., & Duyne, R. P. V. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044087q · Cited by 881

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835

Structural Classification of Toxic Amyloid Oligomers

Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783

A Localized Surface Plasmon Resonance Biosensor: First Steps toward an Assay for Alzheimer's Disease

Haes, A. J., Hall, W. P., Chang, L., Klein, W. L., & Duyne, R. P. V. (2004) · Nano Letters · doi:10.1021/nl049670j · Cited by 715

Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes

Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628

Peptide Fibrillization

Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 624

Amyloid oligomers: formation and toxicity of Aβ oligomers

Sakono, M., & Zako, T. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07568.x · Cited by 633

Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets

Klein, W. L. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00050-5 · Cited by 551

Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid

Chimon, S., Shaibat, M. A., Jones, C. R., Calero, D. C., Aizezi, B., & Ishii, Y. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1345 · Cited by 543

Self-Assembly of Aβ 1 - 42 into Globular Neurotoxins

Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522

Alzheimer's disease: synaptic dysfunction and Aβ

Shankar, G. M., & Walsh, D. M. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-48 · Cited by 486

Small assemblies of unmodified amyloid $beta;-protein are the proximate neurotoxin in Alzheimer?s disease

Klein, W. L., Stine, W. B., & Teplow, D. B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.010 · Cited by 494

Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer’s Disease

Suh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 476

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442

Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers

De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432

Amyloid-β-Induced Pathological Behaviors Are Suppressed byGinkgo bilobaExtract EGb 761 and Ginkgolides in TransgenicCaenorhabditis elegans

Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M. P., Klein, W. L., Link, C. D., & Luo, Y. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3448-06.2006 · Cited by 418

Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?

Lashuel, H. A., & Lansbury, P. T. (2006) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004422 · Cited by 407

Inflammatory Response in the Hippocampus of PS1M146L/APP751SLMouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic

Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383

Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373

Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer’s disease

Tan, M.-S., Tan, L., Jiang, T., Zhu, X.-C., Wang, H.-F., Jia, C.-D., & Yu, J. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.348 · Cited by 351

Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity

Fändrich, M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.006 · Cited by 346

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

Tomic, J. L., Pensalfini, A., Head, E., & Glabe, C. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.024 · Cited by 336

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

Fodero‐Tavoletti, M. T., Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G. J., et al. (2011) · Brain · doi:10.1093/brain/awr038 · Cited by 340

Monoclonal antibodies that target pathological assemblies of Aβ

Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314

Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls

Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2012) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 319

Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1

Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Izzo, N. J., Xu, J., Zeng, C., Kirk, M. J., Mozzoni, K., Silky, C., Rehak, C., Yurko, R., Look, G., Rishton, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111899 · Cited by 157

Sensitive ELISA detection of amyloid‐β protofibrils in biological samples

Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292

Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for β-amyloid peptide over-production and localization in Alzheimer’s disease

Yu, W. H., Kumar, A., Peterhoff, C., Shapiro Kulnane, L., Uchiyama, Y., Lamb, B. T., Cuervo, A. M., & Nixon, R. A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.05.010 · Cited by 279

Protein Misfolded Oligomers: Experimental Approaches, Mechanism of Formation, and Structure-Toxicity Relationships

Bemporad, F., & Chiti, F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.003 · Cited by 275

Inhibition of Amyloid Formation

Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 277

Preparation and characterization of toxic Aβ aggregates for structural and functional studies in Alzheimer's disease research

Jan, A., Hartley, D. M., & Lashuel, H. A. (2010) · Nature Protocols · doi:10.1038/nprot.2010.72 · Cited by 263

Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice

Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 254

Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease

Crouch, P. J., Harding, S.-M. E., White, A. R., Camakaris, J., Bush, A. I., & Masters, C. L. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.013 · Cited by 254

Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity

Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D., Smith, S. O., Ranjan, S., Davis, J., Nostrand, W. E. V., & Tessier, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.329763 · Cited by 228

The Interplay of Catalysis and Toxicity by Amyloid Intermediates on Lipid Bilayers: Insights from Type II Diabetes

Hebda, J. A., & Miranker, A. D. (2009) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.050708.133622 · Cited by 223

Systemic Catabolism of Alzheimer's Aβ40 and Aβ42

Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209

Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer’s disease

Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y., & Ip, N. Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405803111 · Cited by 201

Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization

Felice, F. G. D., Vieira, M. N. N., Saraiva, L. M., Figueroa‐Villar, J. D., Garcia-Abreu, J., Liu, R., Chang, L., Klein, W. L., & Ferreira, S. T. (2004) · The FASEB Journal · doi:10.1096/fj.04-1764com · Cited by 196

Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice

McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., & Dedeoglu, A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.095 · Cited by 201

The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

Wießner, C., Wiederhold, K., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., Jennings, G. T., Lüönd, R. M., Ortmann, R., Reichwald, J., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0293-11.2011 · Cited by 196

Aromatic Small Molecules Remodel Toxic Soluble Oligomers of Amyloid β through Three Independent Pathways

Ladiwala, A. R. A., Dordick, J. S., & Tessier, P. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.173856 · Cited by 194

Preparation of Amyloid β‐Protein for Structural and Functional Studies

Teplow, D. B. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)13002-5 · Cited by 187

Solution State Characterization of Amyloid β-Derived Diffusible Ligands

Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Chen-Dodson, E., Acton, P. J., Keller, P. M., Yeager, M. D., Wang, H., Shughrue, P. J., et al. (2006) · Biochemistry · doi:10.1021/bi061850f · Cited by 182

Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?

Zraika, S., Hull, R. L., Verchere, C. B., Clark, A., Potter, K. J., Fraser, P. E., Raleigh, D. P., & Kahn, S. E. (2010) · Diabetologia · doi:10.1007/s00125-010-1671-6 · Cited by 191

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180

Protein aggregation and neurodegenerative diseases: From theory to therapy

Kumar, V., Sami, N., Kashav, T., Islam, A., Ahmad, F., & Hassan, M. I. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.054 · Cited by 183

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Broersen, K., Rousseau, F., & Schymkowitz, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt36 · Cited by 168

Human neural stem cells alleviate Alzheimer-like pathology in a mouse model

Lee, I.-S., Jung, K., Kim, I., Lee, H.-J., Kim, M., Yun, S., Hwang, K., Shin, J. E., & Park, K. I. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0035-6 · Cited by 170

Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation

Liu, R., McAllister, C., Lyubchenko, Y. L., & Sierks, M. R. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10859 · Cited by 166

Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers

Mannini, B., Cascella, R., Zampagni, M., van Waarde-Verhagen, M. A. W. H., Meehan, S., Roodveldt, C., Campioni, S., Boninsegna, M., Penco, A., Relini, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117799109 · Cited by 164

Aluminum, copper, iron and zinc differentially alter amyloid-Aβ1–42 aggregation and toxicity

Bolognin, S., Luigi Messori, A., Drago, D., Gabbiani, C., Cendron, L., & Zatta, P. F. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.02.009 · Cited by 165

Immunotherapy for Alzheimer's disease

Gélinas, D. S., Silva, K. D., Fenili, D., George‐Hyslop, P. S., & McLaurin, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404866101 · Cited by 161

Conformation-dependent antibodies target diseases of protein misfolding

Glabe, C. C. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.08.009 · Cited by 154

Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes

Limbocker, R., Chia, S., Ruggeri, F. S., Perni, M., Cascella, R., Heller, G. T., Meisl, G., Mannini, B., Habchi, J., Michaels, T. C. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07699-5 · Cited by 154

α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer’s disease

Shea, D. W., Hsu, C.-C., Bi, T., Paranjapye, N., Childers, M. C., Cochran, J., Tomberlin, C., Wang, L., Paris, D., Zonderman, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820585116 · Cited by 152

Structure-based design of conformation- and sequence-specific antibodies against amyloid β

Perchiacca, J. M., Ladiwala, A. R. A., Bhattacharya, M., & Tessier, P. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111232108 · Cited by 147

Synaptotoxic Amyloid-β Oligomers: A Molecular Basis for the Cause, Diagnosis, and Treatment of Alzheimer's Disease?

Klein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 145

New Class of Inhibitors of Amyloid-β Fibril Formation

Lashuel, H. A., Hartley, D. M., Balakhaneh, D., Aggarwal, A. K., Teichberg, S., & Callaway, D. J. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206593200 · Cited by 146

Current progress in beta-amyloid immunotherapy

Schenk, D., Hagen, M., & Seubert, P. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.012 · Cited by 139

Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal

Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134

Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits

Miller, E. C., Teravskis, P. J., Dummer, B. W., Zhao, X., Huganir, R. L., & Liao, D. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12507 · Cited by 131

Alzheimer’s disease as oligomeropathy

Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129

Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease

Pujadas, L., Rossi, D., Andrés, R., Teixeira, C. M., Serra-Vidal, B., Parcerisas, A., Maldonado, R., Giralt, E., Carulla, N., & Soriano, E. (2014) · Nature Communications · doi:10.1038/ncomms4443 · Cited by 129

FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease

Kam, T.-I., Song, S., Gwon, Y., Park, H., Yan, J.-J., Im, I., Choi, J.-W., Choi, T.-Y., Kim, J., Song, D.-K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66827 · Cited by 128

Plasmonic nanoparticles and their analytical applications: A review

Boken, J., Khurana, P., Thatai, S., Kumar, D., & Prasad, S. (2017) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2017.1312427 · Cited by 129

Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides

Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S., & Herne, N. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.013 · Cited by 127

Antibodies against β‐amyloid reduce aβ oligomers, glycogen synthase kinase‐3β activation and τ phosphorylation in vivo and in vitro

Ma, Q., Lim, G. P., Harris‐White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., & Cole, G. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20734 · Cited by 126

Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization

Ryan, T. M., Caine, J. M., Mertens, H. D. T., Kirby, N. M., Nigro, J., Breheney, K., Waddington, L. J., Streltsov, V. A., Curtain, C. C., Masters, C. L., et al. (2013) · PeerJ · doi:10.7717/peerj.73 · Cited by 133

Monoclonal Antibodies against Aβ42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain

Hatami, A., Albay, R., Monjazeb, S., Milton, S. C. F., & Glabe, C. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594846 · Cited by 123

Alzheimer's Disease and the Amyloid β-Protein

Walsh, D. M., & Teplow, D. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00012-6 · Cited by 121

Kinetic characterization of amyloid-beta 1–42 aggregation with a multimethodological approach

Bartolini, M., Naldi, M., Fiori, J., Valle, F., Biscarini, F., Nicolau, D. V., & Andrisano, V. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.03.020 · Cited by 123

Amyloid β oligomerization is induced by brain lipid rafts

Kim, S., Yi, J.-S., & Ko, Y. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20978 · Cited by 121

Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study

Romano, G. L., Platania, C. B. M., Drago, F., Salomone, S., Ragusa, M., Barbagallo, C., Pietro, C. D., Purrello, M., Reibaldi, M., Avitabile, T., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00168 · Cited by 122

The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity

Cecchi, C., & Stefani, M. (2013) · Biophysical Chemistry · doi:10.1016/j.bpc.2013.06.003 · Cited by 117

Amyloid-β oligomers in cellular models of Alzheimer’s disease

Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115

Aggregation Pathways of the Amyloid β(1–42) Peptide Depend on Its Colloidal Stability and Ordered β-Sheet Stacking

Jiang, D., Rauda, I. E., Han, S., Chen, S., & Zhou, F. (2012) · Langmuir · doi:10.1021/la3021436 · Cited by 117

Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue

Bruggink, K. A., Jongbloed, W., Biemans, E. A. L. M., Veerhuis, R., Claassen, J. A. H. R., Kuiperij, H. B., & Verbeek, M. M. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.09.014 · Cited by 114

Single Chain Variable Fragments against β-Amyloid (Aβ) Can Inhibit Aβ Aggregation and Prevent Aβ-Induced Neurotoxicity

Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y. L., Goud, G. N., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi049933o · Cited by 113

MAPK recruitment by β‐amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time

Bell, K. A., O’Riordan, K. J., Sweatt, J. D., & Dineley, K. T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02722.x · Cited by 117

ADDLs and the signaling web that leads to Alzheimer’s disease

Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 113

Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease

Klein, W. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.11.003 · Cited by 109

Monoclonal Antibodies Recognize Distinct Conformational Epitopes Formed by Polyglutamine in a Mutant Huntingtin Fragment

Legleiter, J. A., Lotz, G. P., Miller, J. M. L., Ko, J., Ng, C.-P., Williams, G. L., Finkbeiner, S. M., Patterson, P. H., & Muchowski, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016923 · Cited by 109

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity

Bao, F., Wicklund, L., Lacor, P. N., Klein, W. L., Nordberg, A. K., & Marutle, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.003 · Cited by 112

Molecules that Target beta‐Amyloid

Stains, C. I., Mondal, K., & Ghosh, I. (2007) · ChemMedChem · doi:10.1002/cmdc.200700140 · Cited by 113

Monoclonal antibodies that target pathological assemblies of Aβ

Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314

Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989

[P4–384]: ANTI‐AβX‐40 ANTIBODIES EXERT NEUROPROTECTIVE EFFECT AGAINST Aβ‐OLIGOMER TOXICITY

Montañés, M., Marcos, I., Canudas, J., Lacosta, A. M., Pesini, P., & Sarasa, M. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.2255 · Cited by 1

Anti-Aβ1–11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers

Mamikonyan, G., Necula, M., Mkrtichyan, M., Ghochikyan, A., Petrushina, I., Movsesyan, N., Mina, E. W., Kiyatkin, A. B., Glabe, C. G., Cribbs, D. H., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700088200 · Cited by 95

Immunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in Mice

Mulder, C. K., Dong, Y., Brugghe, H. F., Timmermans, H., Tilstra, W., Westdijk, J., van Riet, E., STEEG, H. V., Hoogerhout, P., & Eisel, U. L. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151136 · Cited by 7